We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Price has been attempted to have been driven down but managed to tread water. Buys seem to be coming in at quite a rate v sells so I see 520p on the ask being breached in short order.
in Shares Magazine which a profit increase forecast. Although the magazine is published on a Thursday, the soggy market today coupled with perhaps readers following its tips once digested could mean some decent buying interest tomorrow if the mood lifts. if so we may breach 520p on the ask. I have a feeling we are only pausing for breath anyway at this level and the 500/520p bid ask is putting a brake on a rise. I certainly expect some buying on the open.
Hi James, Hope it is not deferred as it has been long in the pipeline. The company have made the point that FDA approval is a high barrier to entry as we have seen in the time it is taking TSTL. The German and British Healths ervice demand must be booming and this will also feed into the profits of the company. I think today's fall below 500p is purely technical and I expect a bounce in short order.
I agree that there is a lot more to come, but I think that that applies whatever happens in the sort term with Covid19 issues. I can imagine that that might actually defer FDA approval, as the FDA must be swamped at the moment and the focus will be on a vaccine.
Putting that to one side, the fact is that hospitals etc will need to maintain higher levels of surface disinfection for all time. That aspect of TSTL's offering has been fairly low key so far (compared to medical instrument disinfection). And I hope/expect that TSTL will start to address the huge non-NHS market potential, probably in JV with a major partner. I think that we are still at a fairly early stage in the growth potential for this company.
at 510p/520p bid ask but I think another rise is on the way shortly. Demand is till high and the failure of Gilead's vaccine which was probably the great the great white hope will mean Tristel's products will be in demand for some time to come. Hopefully FDA will drop soon as it has been some time and will surely spark a rerate here.
Strong into the close and some buys at full ask of 520p. In the absence of the market tanking 10% Tristel look good for 550p even before FDA approval. One of the few shares not to sink today even after its recent strong run.
1m sell just gone through at £5.10 @3.52
to remain above in the short term. Been a good run up recently and profit takers can't be blamed for taking 15%. For LTH's like myself it is too risky to be out of with FDA approval looming and perhaps a guidance update. I am sure the current projections will be surpassed by some distance. Quite strong into the close on Friday but although Monday might see 500p breached I question whether it can hold.
Held for about 3 years added some more this year - great company with a moat. Just down the road too.
On the move today getting near year highs with update due soon.
FDA approval covered in the half year results back in Feb but with the latest developments in must surely be bumped up the priority list..
Positive article calling out some of the key strengths of Tristel:
https://www.investorschronicle.co.uk/funds-etfs/2020/04/16/a-great-time-to-start-investing/
I fancy Tristel’s chances over the coming 12/24 months and although the price is a bit toppy I see the potential for significant upside. Here’s hoping! Good luck to all holders.
Very strong buying into the close so I can only assume the IC article only hit home late doors. I have been happily accumulating Tristel in the last six months adding to my longer term holdings. Definitely more upside here and perhaps some follow through buying on Tuesday. I don't know why more speculative money has not gone in here when you see companies like NCYT and Tek and Tils shoot up on the very mention of Covid 19. I will be buying more into the rise.
Tip style
Speculative
Risk rating
High
Timescale
Long Term
Bull points
Rising demand for disinfectant products
Robust barriers to entry
Strong financial track record
Fund manager favourite
Bear points
Competition could intensify with growing global interest in hygiene
Shares are priced for continued excellence
By Harriet Clarfelt
London’s Aim All-Share index has fallen by almost a third over the past three months. But shares in Tristel (TSTL), which are traded on the junior market, remain in positive territory. This can be no coincidence. The group, which was founded in 1993, specialises in infection prevention and contamination control – and its products are in high demand, as countries around the world strive to stop the spread of Covid-19.
TSTL:LSE
Tristel PLC
1mth
Today change
4.82%
Price (GBP)
432.40
Hopefully, concerted efforts will stem the transmission of the novel coronavirus in the months ahead. But, even after this anxious and uncertain period, it seems fair to assume that consumers will maintain extra interest in good hygiene practices. Along with Tristel’s sturdy barriers to entry and strong financial track record, this should position it well to cope with increasing interest in hygiene products.
Besides, Tristel claims a significant competitive advantage. It says it is unique globally in using chlorine dioxide to disinfect medical instruments in hospitals. About four-fifths of group revenues pertain to this practice, which subjects the likes of endoscopes and ultrasound probes to deep, rapid cleaning. Meanwhile, using the same chemistry, Tristel has established a footing in hospital surface disinfection – as well as animal health and in contamination control for critical manufacturing environments.
The group’s economic moat is fortified by the fact that it has various regulatory approvals and a list of proven compatibility with hundreds of medical devices – with equipment manufacturers recommending it as their leading product of choice. These attributes would, arguably, be very difficult to replicate – especially given that Tristel’s expertise is backed up by legal protections. As of last June, it held 277 patents in 36 countries.
In the current climate, it is impossible to say whether analysts’ forecasts will change – regardless of how promising the company’s proposition looks. Still, Tristel has delivered a strong historical performance. Over the past three years, its annual revenue growth has compounded at 15 per cent, while underlying profit has grown at 16 per cent.
The group’s numbers for the six months to December 2019 built upon this strong foundation. Revenues rose by more than a fifth to £14.6m, with underlying pre-tax profits up by a quarter to £3m. The dividend was also up 15 per cent to 2.34p – underpinned by net cash of £4.2m at the period-end even after Tristel paid £0.6m in July to buy the final 80 per cent of ‘Tristel Italia’.
Tristel’s results we
Is the spread always this wide. I know its early in the day but 20p?
yet again. Unless the market thinks the Cov 19 curve is starting to flatten and demand will drop. A bit premature if so and another buying opportunity is presenting itself here. And US approval must be imminent.
Topped up more today, CV is going to continue for many months and Tristel seem to be in a good place to meet the demand. One of these mornings we'll get that RNS with a more detailed update on the marketplace..
of buys but no increase in the ask as yet from 410p. Unless there is a ready seller for the MM's i expect a move up in short order. I think we are just having a lull now before attention comes back on Tristel and the efficacy it brings in the battle against Cov 19. Other shares in that arena such as NCYT (thriving today) and BYOT marginally up seem in demand so I see no reason for TSTL not to have a bite of the cherry.
holding up in a market down day so augurs well. I think today the market is capitalising on a strong rise too soon so value growth stocks in niche arenas will be the recipient of investment when sensible buying returns. I have thought of investing in Byotrol but am sticking with Tristel. Byotrol may be short-lived. Tristel is well proven in the hygiene arena.
Worth topping up on and BYOT. Can see other companies following Tristels lead and getting Byotrols License atleast for one or 2 of their product lines. Should be strong rises in infection control. May spike in a few weeks or months.
Buy note in IC.
Infection prevention specialist Tristel (TSTL) is working with Byotrol (BYOT) – a micro-cap provider of antimicrobial technologies – to develop a new surface disinfectant product for hospitals.
TSTL:LSE
Tristel PLC
1mth
Today change
0.11%
Price (GBP)
446.50
The groups have entered into a ‘know-how’ licence and commercial collaboration to develop a longer-lasting version of Tristel's high-end surface disinfectant. Byotrol's technology can make surface disinfectants effective for up to eight hours. This compares with a current 'kill time' of 30-60 seconds. The new formulations that will be supplied and licensed to Tristel will be branded Tristel8.
IC View
Tristel’s management revealed in the same breath that the group is experiencing very strong demand across its markets because of the coronavirus pandemic. It said that as a UK manufacturer with very little exposure to international supply chains, and with adequate productive capacity, it is well positioned to meet the requirements of its customers. In unprecedented and uncertain times, mirrored by volatile markets, Tristel is one of the few to be cleaning up – quite literally. For now, we remain optimistic. At 459p, buy.
New Relevant life saving product for UK based company with large overseas order potential + a dividend.
You have my support. Well done LTH's.
though I wish I had been braver into the falls. More to come here I think as today gives an extra string to the bow. Ex divi coming up so I will be reinvesting my divis straight back in
Trading- "With respect to current trading conditions, we are experiencing very strong demand in all our markets due to the COVID-19 pandemic. As a UK manufacturer with very little exposure to convoluted international supply chains, and adequate productive capacity, we are well placed to meet the requirements of our customers in the UK and overseas''
Byotrol-
Negative - They will need to pay a licence to Byotrol for some ingredients for their intermediate disinfectants to keep with regulation changes -
Positive -Novel longer lasting products -Tristel8
Very positive update - for both the short and the longer term. Just need FDA to expediate clearance.
Nice little update in the last paragraph of the RNS...